CA4 and colorectal carcinoma: Regulators or inhibitors of m6A modifications may provide the potential therapeutic strategies for cancers, such as MA2 in GBM [74], R-2HG/SPI1/FB23–2 in AML [24, 68, 82] and CA4 in CRC [81].